{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:49:43Z","timestamp":1770832183543,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangdong Science and Technology Project Fund for Key Fields in Scientific Research","award":["2019B020230001"],"award-info":[{"award-number":["2019B020230001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Capecitabine is widely used in chemotherapy for breast, colorectal, and gastric cancers. The frequent adverse reactions of capecitabine mainly include gastrointestinal side effects, anemia, and cardiovascular toxicity. Here, we report a rare case of severe hyperglycemia and hypokalemia during long-term treatment with capecitabine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 48-year-old Chinese female was hospitalized with the complaint of breathlessness and weakness after activity, for 1 month. Her past history is significant for a diagnosis of right-sided breast cancer 7 years ago. She underwent right mastectomy, following which capecitabine was started 1.5 years prior to the current admission as part of her primary treatment at the discovery of systemic osseous metastasis. Her fasting plasma glucose and hemoglobin A1c levels were quite normal 7 months ago but increased to 15.3 mmol\/L and 11.2%, respectively, at the present admission. Her serum potassium level was as low as 2.5 mmol\/L. Plasma autoantibodies related to islets and insulin were all negative. Capecitabine was discontinued, and an insulin pump and potassium supplement were given after admission. Her blood sugar and potassium levels returned to their normal ranges soon. Self-injection of insulin was withdrawn completely at 2 months after discharge, and no oral hypoglycemic agents were added. Her plasma glucose and electrolyte levels were at normal levels at her 1-year follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Glucose intolerance and hypokalemia may be rare but serious adverse effects during long-term chemotherapy with capecitabine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03392-w","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T23:04:47Z","timestamp":1650841487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Capecitabine-induced severe diabetes and hypokalemia: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Qiaoling","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1364-9469","authenticated-orcid":false,"given":"Jianmin","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"issue":"1","key":"3392_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23\u201344.","journal-title":"Clin Ther"},{"issue":"12","key":"3392_CR2","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1001\/archdermatol.2011.320","volume":"147","author":"FJ Hoesly","year":"2011","unstructured":"Hoesly FJ, Baker SG, Gunawardane ND, Cotliar JA. Capecitabine-induced hand\u2013foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. Arch Dermatol. 2011;147(12):1418\u201323.","journal-title":"Arch Dermatol"},{"issue":"22","key":"3392_CR3","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359.","journal-title":"N Engl J Med"},{"issue":"3","key":"3392_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10549-019-05513-4","volume":"179","author":"Y Li","year":"2020","unstructured":"Li Y, Zhou Y, Mao F, Lin Y, Zhang X, Shen S, et al. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis. Breast Cancer Res Treat. 2020;179(3):533\u201342.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"3392_CR5","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/annonc\/mdh467","volume":"15","author":"D Hess","year":"2004","unstructured":"Hess D, Th\u00fcrlimann B, Pagani O, Aebi S, Rauch D, Ballabeni P, et al. Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25\/99). Ann Oncol. 2004;15(12):1760\u20135.","journal-title":"Ann Oncol"},{"issue":"12","key":"3392_CR6","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"issue":"12","key":"3392_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1464-5491.2009.02842.x","volume":"26","author":"R Garg","year":"2009","unstructured":"Garg R, Angus E, Fincher S. Capecitabine-induced severe hypertriglyceridemia and diabetes: a case report and review of the literature. Diabet Med. 2009;26(12):1308\u20139.","journal-title":"Diabet Med"},{"key":"3392_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2016.08.001","volume":"50","author":"SW Lam","year":"2016","unstructured":"Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9\u201322.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"3392_CR9","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0959-8049(97)00256-6","volume":"33","author":"CH K\u00f6hne","year":"1997","unstructured":"K\u00f6hne CH, Harstrick A, Hiddemann W, Sch\u00f6ffski P, Wilke H, Bokemeyer C, et al. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-l-aspartate in patients with advanced colorectal cancer. Results of a phase II study. Eur J Cancer. 1997;33(11):1896\u20139.","journal-title":"Eur J Cancer"},{"issue":"7","key":"3392_CR10","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.4239\/wjd.v12.i7.1010","volume":"12","author":"C Yim","year":"2021","unstructured":"Yim C, Mansell K, Hussein N, Arnason T. Current cancer therapies and their influence on glucose control. World J Diabetes. 2021;12(7):1010\u201325.","journal-title":"World J Diabetes"},{"issue":"1","key":"3392_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1463-1318.2012.03097.x","volume":"15","author":"JP Feng","year":"2013","unstructured":"Feng JP, Yuan XL, Li M, Fang J, Xie T, Zhou Y, et al. Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. Colorectal Dis. 2013;15(1):27\u201333.","journal-title":"Colorectal Dis"},{"issue":"6 Suppl","key":"3392_CR12","doi-asserted-by":"publisher","first-page":"65S","DOI":"10.1177\/014860719201600606","volume":"16","author":"JA Tayek","year":"1992","unstructured":"Tayek JA, Chlebowski RT. Metabolic response to chemotherapy in colon cancer patients. JPEN J Parenter Enteral Nutr. 1992;16(6 Suppl):65S-71S.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"12","key":"3392_CR13","first-page":"935","volume":"13","author":"JP Feng","year":"2010","unstructured":"Feng JP, Chen JG, Yuan XL, Wang YP, Fang J, Liu C. Impact of 5-fluorouracil on glucose metabolism and pancreatic pathology in rats. Zhonghua Wei Chang Wai Ke Za Zhi. 2010;13(12):935\u20138.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"issue":"8","key":"3392_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1592\/phco.23.8.1076.32870","volume":"23","author":"KL Jones","year":"2003","unstructured":"Jones KL, Valero V. Capecitabine-induced pancreatitis. Pharmacotherapy. 2003;23(8):1076\u20138.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"3392_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/tcrm.2007.3.1.177","volume":"3","author":"MW Saif","year":"2007","unstructured":"Saif MW, Fekrazad MH, Ledbetter L, Diasio RB. Hypokalemia secondary to capecitabine: a hidden toxicity? Ther Clin Risk Manag. 2007;3(1):177\u201380.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"3392_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s10147-010-0050-0","volume":"15","author":"A Sonnenblick","year":"2010","unstructured":"Sonnenblick A, Meirovitz A. Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature. Int J Clin Oncol. 2010;15(4):420\u20132.","journal-title":"Int J Clin Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03392-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03392-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03392-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T23:04:52Z","timestamp":1650841492000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03392-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3392"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03392-w","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests related to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}